Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$173.00 USD

173.00
994,173

-0.27 (-0.16%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $172.98 -0.02 (-0.01%) 4:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised

by Zacks Equity Research

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Zacks Equity Research

BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket

by Zacks Equity Research

Bruker delivers robust revenue growth in the third quarter despite soft general market conditions.

Zacks Equity Research

BDX Stock Gains Following Q4 Earnings Beat and Higher Margins

by Zacks Equity Research

BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.

Zacks Equity Research

QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up

by Zacks Equity Research

QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.

Zacks Equity Research

STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket

by Zacks Equity Research

STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning.

Zacks Equity Research

Phibro's Q1 Earnings Top Estimates, Stock Up, Net Sales Surge Y/Y

by Zacks Equity Research

PAHC delivers strong growth across all its segments in the first quarter of fiscal 2025.

Zacks Equity Research

Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall

by Zacks Equity Research

CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.

Zacks Equity Research

CVS Health Q3 Earnings & Revenues Beat, Stock Rises in Premarket

by Zacks Equity Research

CVS' third-quarter 2024 results reflect strong performance in the Health Services and Pharmacy & Consumer Wellness segments.

Zacks Equity Research

Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y

by Zacks Equity Research

COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.

Zacks Equity Research

Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises

by Zacks Equity Research

FMS' third-quarter results showcase a strong segmental performance. The company raises its full-year 2024 outlook for operating income.

Zacks Equity Research

MASI Stock Gains Following Q3 Earnings Beat, Gross Margin Expands

by Zacks Equity Research

Masimo's third-quarter 2024 results continue to benefit from the strength in its Healthcare business.

Zacks Equity Research

Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up

by Zacks Equity Research

CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading.

Zacks Equity Research

Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut

by Zacks Equity Research

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.

Zacks Equity Research

GMED Q3 Earnings Top, '24 Guidance Raised, Stock Gains in Aftermarket

by Zacks Equity Research

Globus Medical delivers massive sales and earnings growth in the third quarter of 2024. However, margins contract.

Zacks Equity Research

Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure

by Zacks Equity Research

IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter.

Zacks Equity Research

Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.

Zacks Equity Research

GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.

Zacks Equity Research

HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts

by Zacks Equity Research

Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.

Zacks Equity Research

INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.

Zacks Equity Research

Hologic Q4 Earnings Lag, Revenues Top, Stock Down in Aftermarket

by Zacks Equity Research

HOLX's fiscal 2024 fourth-quarter results underscore the durable growth of its businesses.

Zacks Equity Research

RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised

by Zacks Equity Research

Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.

Zacks Equity Research

Here's Why You Should Retain DGX Stock in Your Portfolio Now

by Zacks Equity Research

Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging.

Zacks Equity Research

BDX Stock Declines Despite Launching BD IO Vascular Access System

by Zacks Equity Research

BD announces the BD Intraosseous Vascular Access System to enable quick vascular access for critical care situations.

Zacks Equity Research

Teleflex Q3 Earnings Top, Stock Falls on Lowered 2024 Revenue Outlook

by Zacks Equity Research

TFX benefits from a diversified product portfolio in the third quarter of 2024, with strength in the Vascular Access and Interventional segments.

Zacks Equity Research

OMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised

by Zacks Equity Research

Omnicell continues its trend of impressive results in the third quarter of 2024.